Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation
IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR)
19 or 21 exon mutation treated Erlotinib vs NP chemotherapy as adjuvant therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital